Cargando…

Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?

The emergent outbreak of coronavirus disease 2019 (COVID-19) has caused a global pandemic. Acute respiratory distress syndrome (ARDS) and multiorgan dysfunction are among the leading causes of death in critically ill patients with COVID-19. The elevated inflammatory cytokines suggest that a cytokine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Bingwen, Li, Min, Zhou, Zhiguang, Guan, Xuan, Xiang, Yufei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151347/ https://www.ncbi.nlm.nih.gov/pubmed/32291137 http://dx.doi.org/10.1016/j.jaut.2020.102452

Ejemplares similares

Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)?
por: Liu, Danfei, et al.
Publicado: (2020)

Interleukin-6 signaling blockade treatment for cytokine release syndrome in COVID-19 (Review)
por: Chen, Jia-Jie, et al.
Publicado: (2021)

Less Can Be More When Targeting Interleukin-6-Mediated Cytokine Release Syndrome in Coronavirus Disease 2019
por: Betts, Brian C., et al.
Publicado: (2020)

The deregulated immune reaction and cytokines release storm (CRS) in COVID-19 disease
por: Pasrija, Ritu, et al.
Publicado: (2021)

Interleukin-6 Antagonist Tocilizumab to Treat Critically Ill Coronavirus Disease 2019 Patients With Cytokine Release Syndrome: A Case Series
por: Yang, Stephen Su, et al.
Publicado: (2021)

Cytokine Release Syndrome (CRS) and Nicotine in COVID-19 Patients: Trying to Calm the Storm
por: Gonzalez-Rubio, Jesus, et al.
Publicado: (2020)

Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
por: Leclercq-Cohen, Gabrielle, et al.
Publicado: (2023)

Implications of Interleukin-6 (IL-6)-blockade for severe COVID-19 infection in patients with Multiple Myeloma
por: Sgherza, Nicola, et al.
Publicado: (2021)

Cytokine Blockade in Coronavirus Disease 2019: Keeping an Open Mind
por: Szakmany, Tamas, et al.
Publicado: (2021)

Sepsis-associated severe interleukin-6 storm in critical coronavirus disease 2019
por: Huang, Lan, et al.
Publicado: (2020)

Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials
por: Stewart, Mark D., et al.
Publicado: (2022)

Interleukin-6 (IL-6) inhibitors as therapeutic agents for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis
por: Pinzon, Rizaldy Taslim, et al.
Publicado: (2021)

IL12 immune therapy clinical trial review: Novel strategies for avoiding CRS-associated cytokines
por: Jia, Zhiliang, et al.
Publicado: (2022)

The conundrum of interleukin-6 blockade in COVID-19
por: Campochiaro, Corrado, et al.
Publicado: (2020)

The role of interleukin‐6 in monitoring severe case of coronavirus disease 2019
por: Liu, Tao, et al.
Publicado: (2020)

Special issue on Interleukin-6 (IL-6)
por: Rincon, Mercedes
Publicado: (2012)

Therapeutic Potential of TNFα and IL1β Blockade for CRS/ICANS in CAR-T Therapy via Ameliorating Endothelial Activation
por: Chen, Yunshuo, et al.
Publicado: (2021)

An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19)
por: Elahi, Reza, et al.
Publicado: (2022)

Preemptive interleukin-6 blockade in patients with COVID-19
por: Guillén, Lucía, et al.
Publicado: (2020)

Rethinking interleukin-6 blockade for treatment of COVID-19
por: Scherger, S., et al.
Publicado: (2020)

Interleukin-6 level, right ventricular systolic dysfunction, and coronavirus disease 2019
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Elevated interleukin‐6, interleukin‐10 and neutrophil : lymphocyte ratio as identifiers of severe coronavirus disease 2019
por: Godkin, Andrew, et al.
Publicado: (2020)

Cytokine Release Syndrome (CRS) in Severe COVID-19 Patients: Two Controversial and Interesting Case Reports and Literature Review
por: Lazovic, Biljana, et al.
Publicado: (2023)

CD27-IgD- memory B cells are modulated by in vivo interleukin-6 receptor (IL-6R) blockade in rheumatoid arthritis
por: Mahmood, Zafar, et al.
Publicado: (2015)

Ga(III) Nanoparticles Inhibit Growth of both Mycobacterium tuberculosis and HIV and Release of Interleukin-6 (IL-6) and IL-8 in Coinfected Macrophages
por: Choi, Seoung-ryoung, et al.
Publicado: (2017)

Interleukin-6-knockdown of chimeric antigen receptor-modified T cells significantly reduces IL-6 release from monocytes
por: Kang, Liqing, et al.
Publicado: (2020)

Interleukin-6: discovery of a pleiotropic cytokine
por: Kishimoto, Tadamitsu
Publicado: (2006)

Historical overview of the interleukin-6 family cytokine
por: Kang, Sujin, et al.
Publicado: (2020)

Statins potently reduce the cytokine-mediated IL-6 release in SMC/MNC cocultures
por: Loppnow, Harald, et al.
Publicado: (2011)

Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndrome
por: Du, Peng, et al.
Publicado: (2021)

Role of interleukin 4 (IL4) and interleukin 6 (IL6) in the pathogenesis and prognosis of childhood primary immune thrombocytopenia
por: Zakaria, Marwa, et al.
Publicado: (2023)

Investigation of CRS-associated cytokines in CAR-T therapy with meta-GNN and pathway crosstalk
por: Wei, Zhenyu, et al.
Publicado: (2022)

Cathepsin S provokes interleukin-6 (IL-6) trans-signaling through cleavage of the IL-6 receptor in vitro
por: Flynn, Charlotte M., et al.
Publicado: (2020)

Relevance of Inflammatory Cytokine mRNA Expression of Tumour Necrosis Factor- Alpha (TNF α), Interleukin 17A (IL 17A) and Interleukin 6 (IL 6) in Indian Patients with Psoriasis
por: Shah, Saiqa R., et al.
Publicado: (2022)

Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis.
por: Robak, T, et al.
Publicado: (1998)

Functional and Morphological Improvement of Dystrophic Muscle by Interleukin 6 Receptor Blockade
por: Pelosi, Laura, et al.
Publicado: (2015)

Role of interleukin-6 (IL-6) in predicting gestational diabetes mellitus
por: Amirian, Azam, et al.
Publicado: (2020)

A Non-severe Coronavirus Disease 2019 Patient With Persistently High Interleukin-6 Level
por: Hambali, Nurfarah Lydia, et al.
Publicado: (2020)

Interleukin-6 in Critical Coronavirus Disease 2019, a Driver of Lung Inflammation of Systemic Origin?
por: Aarskog, Nikolai Ravn, et al.
Publicado: (2021)

In vitro IL-6/IL-6R Trans-Signaling in Fibroblasts Releases Cytokines That May Be Linked to the Pathogenesis of IgG4-Related Disease
por: Zongfei, Ji, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ps4g7qmlu5g2flb3t3st215bkh